Otsuka Pharmaceutical Development & Commercialization, Inc.

This study looked at the long-term safety of an experimental drug, AVP-786, for treating agitation in people with Alzheimer's disease. It was an extension of earlier phase 3 studies and involved about 1,200 participants. The study was terminated, meaning it stopped early, and the…

This study tested an experimental drug called AVP-786 to see if it could safely reduce disinhibition—acting impulsively or inappropriately—in people with brain disorders like Alzheimer's or dementia. Only one person enrolled before the trial was stopped early. The main goal was t…